A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2018
At a glance
- Drugs Mirvetuximab soravtansine (Primary)
- Indications Adenocarcinoma; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors ImmunoGen
- 06 Jun 2018 Planned End Date changed from 1 Mar 2018 to 1 Apr 2019.
- 19 Dec 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
- 19 Dec 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jan 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History